Search Results - "Badimon, Juan J."

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics by Santos-Gallego, Carlos G., Requena-Ibanez, Juan Antonio, San Antonio, Rodolfo, Ishikawa, Kiyotake, Watanabe, Shin, Picatoste, Belen, Flores, Eduardo, Garcia-Ropero, Alvaro, Sanz, Javier, Hajjar, Roger J., Fuster, Valentin, Badimon, Juan J.

“…Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be…”
Get full text

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction by Santos-Gallego, Carlos G., Requena-Ibáñez, Juan Antonio, Picatoste, Belen, Fardman, Brian, Ishikawa, Kiyotake, Mazurek, Renata, Pieper, Michael, Sartori, Samantha, Rodriguez-Capitán, Jorge, Fuster, Valentin, Badimon, Juan J.

“…SGLT2i (sodium-glucose cotransporter-2 inhibitors) improve clinical outcomes in patients with heart failure, but the mechanisms of action are not completely…”
Get full text

Metabolism of the failing heart and the impact of SGLT2 inhibitors by Garcia-Ropero, Alvaro, Santos-Gallego, Carlos G, Zafar, M Urooj, Badimon, Juan J

“…Cardiac metabolism represents a complex network of numerous pathways responsible for an adequate supply of ATP to the incessant contractile apparatus…”
Get more information

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors by Vargas-Delgado, Ariana P, Arteaga Herrera, Estefania, Tumbaco Mite, Cesar, Delgado Cedeno, Patricia, Van Loon, Maria Cristina, Badimon, Juan J

“…Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus…”
Get full text

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance by García-Ropero, Álvaro, Vargas-Delgado, Ariana P, Santos-Gallego, Carlos G, Badimon, Juan J

“…The sodium-glucose cotransporter (SGLT) inhibitors represent a new alternative for treating patients with diabetes mellitus. They act primarily by inhibiting…”
Get full text

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease by Badimon, Juan J, Escolar, Gines, Zafar, M Urooj

“…Despite major advancements in the development of safer and more effective anticoagulant agents, bleeding complications remain a significant concern in the…”
Get full text

The anti-inflammatory effects of SGLT inhibitors by García-Ropero, Álvaro, Santos-Gallego, Carlos G, Badimon, Juan J

Get full text

Cardiac Complications After Community-Acquired Pneumonia by Santos-Gallego, Carlos G., MD, Badimon, Juan J., PhD

“…The investigators have previously demonstrated a high MI rate (especially of silent MI) in patients with CAP during the first days of hospitalization.2 This MI…”
Get full text

Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression by Zafar, M. Urooj, Paz-Yepes, Manuel, Shimbo, Daichi, Vilahur, Gemma, Burg, Matthew M., Chaplin, William, Fuster, Valentin, Davidson, Karina W., Badimon, Juan J.

“…Aims Depression and anxiety are linked to coronary events but the mechanism(s) remains unclear. We investigated the associations of depression and anxiety with…”
Get full text

Accelerated reendothelialization, increased neovascularization and erythrocyte extravasation after arterial injury in BAMBI-/- mice by Guillot, Nicolas, Kollins, Dmitrij, Badimon, Juan J, Schlondorff, Detlef, Hutter, Randolph

“…Intimal injury rapidly activates TGFβ and enhances vascular repair by the growth of endothelial (EC) and vascular smooth muscle cells (VSMC). The response to…”
Get full text

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber by Zafar, Mohammad Urooj, Vorchheimer, David A, Gaztanaga, Juan, Velez, Mauricio, Yadegar, Daniel, Moreno, Pedro R, Kunitada, Satoshi, Pagan, Juan, Fuster, Valentin, Badimon, Juan J

“…Direct and specific inhibition of factor Xa is an emerging therapeutic strategy for atherothrombotic disease. Parenteral factor Xa inhibitors promise efficacy…”
Get more information

New approaches to triglyceride reduction: Is there any hope left? by Filtz, Annalisa, Parihar, Siddhant, Greenberg, Garred S., Park, Christine M., Scotti, Andrea, Lorenzatti, Daniel, Badimon, Juan J, Soffer, Daniel E., Toth, Peter P., Lavie, Carl J., Bittner, Vera, Virani, Salim S., Slipczuk, Leandro

“…Triglycerides play a crucial role in the efficient storage of energy in the body. Mild and moderate hypertriglyceridemia (HTG) is a heterogeneous disorder with…”
Get full text

Beginning to Understand High-Density Lipoproteins by Santos-Gallego, Carlos G., MD, Badimon, Juan J., PhD, Rosenson, Robert S., MD

“…This article reconciles the classic view of high-density lipoproteins (HDL) associated with low risk for cardiovascular disease (CVD) with recent data…”
Get full text

Spark That Lights the Fire: Infection Triggers Cardiovascular Events by Santos-Gallego, Carlos G, García-Ropero, Álvaro, Badimon, Juan J

“…See Article by Cowan et al…”
Get full text

The Sum of Two Evils by Santos-Gallego, Carlos G., MD, Badimon, Juan J., PhD

“…[...]in the 41% of patients without electrocardiographic changes, increased hs-cTnT is probably not secondary to ischemia. In the GRAVITAS (Gauging…”
Get full text

The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion by Ibanez, Borja, Cimmino, Giovanni, Prat-González, Susanna, Vilahur, Gemma, Hutter, Randolph, García, Mario J, Fuster, Valentin, Sanz, Javier, Badimon, Lina, Badimon, Juan J

“…Abstract Background Myocardial infarct size is a strong predictor of cardiovascular events. Intravenous metoprolol before coronary reperfusion has been shown…”
Get full text

Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis by Giannarelli, Chiara, Cimmino, Giovanni, Connolly, Thomas M., Ibanez, Borja, Garcia Ruiz, Josè M., Alique, Matilde, Zafar, M. Urooj, Fuster, Valentin, Feuerstein, Giora, Badimon, Juan J.

“…Aims The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist,…”
Get full text

Targeting thrombogenicity and inflammation in chronic HIV infection by O'Brien, Meagan P, Zafar, M Urooj, Rodriguez, Jose C, Okoroafor, Ibeawuchi, Heyison, Alex, Cavanagh, Karen, Rodriguez-Caprio, Gabriela, Weinberg, Alan, Escolar, Gines, Aberg, Judith A, Badimon, Juan J

“…Persons with HIV infection (PWH) have increased risk for cardiovascular disease (CVD), but the underlying mechanisms remain unclear. Coronary thrombosis is…”
Get full text

Diagnosis of Atherosclerosis by Imaging by Ibañez, Borja, MD, Badimon, Juan J., PhD, Garcia, Mario J., MD

“…Abstract New and experimental imaging techniques are being developed that will permit better visualization and compositional characterization of atheromatous…”
Get full text

Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review by Yurista, Salva R, Chong, Cher-Rin, Badimon, Juan J, Kelly, Daniel P, de Boer, Rudolf A, Westenbrink, B Daan

“…Metabolic perturbations underlie a variety of cardiovascular disease states; yet, metabolic interventions to prevent or treat these disorders are sparse…”
Get full text